

## Amendment

### In the specification

Please replace the paragraph at page 4, lines 1-8, with the following paragraph.

By "HLA-binding" peptide we mean a peptide which binds to one or more HLA molecules. Typically, a peptide will show HLA binding in a T2 binding assay when present in a concentration range of 10  $\mu$ M to 1 nM. Whether or not a peptide of human CD45 is an HLA-binding peptide can be determined using methods known in the art. These methods include the T2 HLA stabilisation assay described in ~~Figure 1~~ Figures 1A and 1B, and the method described by Elvin *et al* (1993) *J. Immunol. Methods* **158**, 161-171.

Please replace the paragraph at page 31, lines 4-9, with the following paragraph.

~~Figure 1 shows~~ Figures 1A and 1B show the result of an assay to measure HLA-A0201 binding of peptides. Peptide binding was measured using the T2 assay that is based on the ability of peptides to stabilise HLA-A0201 expression in the TAP-deficient T2 cells. The peptide 1218 (FLYDVIAST, SEQ ID NO:1) was one of the best binders and was used to stimulate CTL responses (see Figure 2).


Please replace the paragraph at page 32, lines 15-17, with the following paragraph.

Sixteen peptides of the CD45 molecule were selected and 14 of them we tested in HLA-A0201 binding assays as described in the ~~legend to Figure 1~~ legends to Figures 1A and 1B. Twelve of the peptides showed binding activity (see ~~Figure 1~~ Figures 1A and 1B).

U.S.S.N.: 10/003,983  
Filed: October 31, 2001  
**TRANSMITTAL OF FORMAL DRAWINGS**

The specification has been amended to conform the specification to the formal drawings as filed. No new matter has been added.

Respectfully submitted,



---

Tiffany B. Salmon  
Reg. No. 55,589

Date: December 3, 2004

PABST PATENT GROUP LLP  
400 Colony Square, Suite 1200  
1201 Peachtree Street  
Atlanta, Georgia 30361  
(404) 879-2153 (Telephone)  
(404) 879-2160 (Fax)